Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436189 · ClinicalTrials.gov registry record · NA
Assess Cancer in Ovarian Tumors With Biomarkers.
A NA study of Ovarian Tumor, sponsored by Ciphergen Biosystems.
- Completed
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 18
- Study locations
NCT00436189: Completed NA study of Ovarian Tumor, sponsored by Ciphergen Biosystems.
NCT00436189 is a NA study of Ovarian Tumor that has completed, run by Ciphergen Biosystems. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00436189, a NA study of Ovarian Tumor, has completed, sponsored by Ciphergen Biosystems.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 18
- Study locations
Study Summary
Purpose The OvaRI assay clinical trial is directed at evaluating a novel proteomics-based blood test. This test is for a physician to use towards differentiating benign from malignant ovarian tumors prior to surgical intervention. Tools that can better triage women with an ovarian tumor are needed. It has been shown that women with ovarian cancer who are referred to gynecologic oncologists have better outcomes. The primary objective of this study is to demonstrate that the OvaRl assay (test) improves the preoperative identification of ovarian cancer in patients with a ovarian tumor.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
Study Locations (18)
Arizona
- Women's Health Research - Phoenix
- Precision Trials - Phoenix
California
- Gynecologic Oncology Associates - Newport Beach
- North Coast Women's Care Medical Group Inc - Vista
Connecticut
- Farmington Obstetrics and Gynecology Group - Avon
- The GYN Center for Women's Health - Waterbury
Florida
- Florida Hospital Cancer Institute - Orlando
- OB/GYN Specialists of the Palm Beaches - West Palm Beach
Texas
- SWRCC - Austin
- UT South Western Medical Center at Dallas - Dallas
Alabama
- Clinical Research Consultants - Hoover
Kentucky
- University of Kentucky - Whitney Facility - Lexington
Maine
- Maine Medical Center - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-04 |
| Phase | NA |
What the finished NCT00436189 record still lists
NCT00436189 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Ovarian Tumor appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT00436189 lists 18 locations in 13 states (Arizona, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT00436189 about?
NCT00436189 is a clinical study titled "Assess Cancer in Ovarian Tumors With Biomarkers.". Purpose The OvaRI assay clinical trial is directed at evaluating a novel proteomics-based blood test. This test is for a physician to use towards differentiating benign from malignant ovarian tumors prior to surgical intervention. Tools that can better triage women with an ovarian tumor are needed....
What is the current status of trial NCT00436189?
This trial is currently completed. It is a NA study. The enrollment target is 1,000 participants. The study started on 2007-02. Estimated completion is 2008-04.
What conditions does trial NCT00436189 study?
This clinical trial studies the following conditions: Ovarian Tumor.
What interventions are being tested in trial NCT00436189?
The interventions under investigation include: Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT00436189?
This trial is sponsored by Ciphergen Biosystems, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00436189 being conducted?
This trial has 18 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00436189's enrollment target sits among peer trials
1,000 107th of 2000 higher than 1,880 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia